Pharmaceuticals. 2020, 13, 186.

Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.

Bioorg. Med. Chem., 2009, 17(18), 6715-6727.

Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents.

 J. Enz. Inh. Med. Chem.2008, 23(5), 686-695.

Side chain modifications of (indol-3-yl)glyoxamides as antitumor agents.

J. Enz. Inh. Med. Chem. 2008, 23(5), 728-738.

N-Pyridinyl(methyl)-indole-1- or 3-propanamides and propenamides acting as topical and systemic anti-inflammatory inhibitors.

J. Enz. Inh. Med. Chem. 2007, 22(5), 667-676.

Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors. 

Bioorg. Med. Chem. Lett. 2007,17(13), 3686-3689.

Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety.

Bioorg. Med. Chem. Lett. 2006, 16, 1134-1137.

Synthesis and biologicol evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: Potent and selective aromatase inhibitors.

Tetrahedron Lett. 2006, 47, 6479-6483.

Efficient microwave-assisted synthesis of 2-phenyl-1-(1H-indol-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol derivatives with potential antifungal activity.

J. Enz. Inh. Med. Chem. 2005, 20, 581-585.

Three-Dimensional Model of Cytochrome P450 Human Aromatase.

Mycology 2004, 11 (supplement 1), 43.

Antifungal activity of new azolylindole derivatives against Candida and Aspergillus. Proceedings of the 10th Congress of the European Confederation of Medical

J. Enz. Inh. Med. Chem. 2004, 19, 451-457.

Synthesis and antileishmanial activity of 3-imidazolylalkylindoles. Part I.

J. Enz. Inh. Med. Chem. 2004, 19, 549-557.

2- and 3-[(Aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors.

Med. Chem. Lett. 2004, 14, 5441-5444.

New N-pyridinyl(methyl)-indolalkanamides acting as topical inflammation inhibitors. Bioorg.

Eur. J. Med. Chem. 2003, 38, 711-718.

Synthesis and antileismanial activity of new imidazolidin-2-one derivatives.

Eur. J. Med. Chem. 2003, 38, 75-87.

Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives.

Bioorg. Med. Chem. Lett. 2003, 13, 1553-1555.

Preparation and Pharmacological Profile of 7-(a-Azolylbenzyl)-1H-Indoles and Indolines as New Aromatase Inhibitors.

J. Enz. Inh. Med. Chem. 2003, 18, 155-158.

Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2,3 or 5-(a-azolylbenzyl)-1H-indoles.

J. Enz. Inh. Med. Chem. 2003, 18, 201-208.

New N-pyridinyl (methyl) N1-substituted-3-indolylpropanamides acting as topical and systemic inflammation inhibitors.

J. Enz. Inh. Med. Chem. 2003, 18, 253-257.

Potential Inhibitors of Angiogenesis. Part II: 3-(Azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones.

J. Enz. Inh. Med. Chem. 2003, 18, 243-252. 

Potential Inhibitors of Angiogenesis. Part I: 3-(Imidazol-4(5)-yl methylene)indolin-2-ones.

Brevet US 2004067998 A1 publié le 8 avril 2004.

Brevet CN 1473160A publié le 4 février 2004.

Brevet EP 1322638 publié le 2 juillet 2003.

Brevet CA 2 423 151 A1 publié le 21 mars 2003.

Fr. Pat. n° 02.01409, 06 Feb. 2002.

Brevet PCT WO 02/24685 A1 déposé le 21 septembre 2001, publié le 28 mars 2002.

Brevet FR 2 814 073 - A1 déposé le 21 septembre 2000, publié le 22 mars 2002.